Guinness Asset Management LTD Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Guinness Asset Management LTD raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 2.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,237 shares of the medical research company’s stock after purchasing an additional 951 shares during the period. Guinness Asset Management LTD’s holdings in Thermo Fisher Scientific were worth $25,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of TMO. Widmann Financial Services Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at about $26,000. Mystic Asset Management Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $29,000. Lee Financial Co acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $32,000. Costello Asset Management INC acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $33,000. Finally, Sumitomo Mitsui Financial Group Inc. boosted its holdings in Thermo Fisher Scientific by 141.7% in the fourth quarter. Sumitomo Mitsui Financial Group Inc. now owns 58 shares of the medical research company’s stock worth $38,000 after acquiring an additional 34 shares in the last quarter. Institutional investors own 87.48% of the company’s stock.

TMO has been the subject of several recent analyst reports. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $605.00 to $525.00 in a report on Monday, April 25th. StockNews.com started coverage on Thermo Fisher Scientific in a report on Thursday, March 31st. They set a “hold” rating for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $658.92.

Thermo Fisher Scientific stock opened at $519.22 on Thursday. The stock has a market capitalization of $203.25 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 12 month low of $489.14 and a 12 month high of $672.34. The business has a 50 day simple moving average of $544.31 and a 200-day simple moving average of $575.26. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical research company reported $7.25 EPS for the quarter, beating analysts’ consensus estimates of $6.17 by $1.08. The business had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The business’s revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business earned $7.21 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 0.23%. The ex-dividend date is Tuesday, June 14th. Thermo Fisher Scientific’s payout ratio is 6.26%.

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 200 shares of the company’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $544.36, for a total value of $108,872.00. Following the completion of the sale, the director now directly owns 810 shares in the company, valued at approximately $440,931.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $545.60, for a total value of $5,456,000.00. Following the completion of the transaction, the chief executive officer now directly owns 183,373 shares in the company, valued at approximately $100,048,308.80. The disclosure for this sale can be found here. Insiders have sold 42,561 shares of company stock valued at $23,557,413 over the last quarter. 0.43% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.